Entrada Therapeutics, Inc. Common Stock TRDA
Analyst Ratings
- Consensus
- Moderate Buy — 2 Buy · 1 Hold · 0 Sell (3 analysts)
- Avg. Price Target
- $20.00 (+292.5% upside)
Key Stats
- Today's Range
- $4.79 – $5.20
- 50-Day Range
- $4.11 – $7.79
- 52-Week Range
- $4.11 – $16.45
- Volume
- 55K shs
- Average Volume
- 345K shs
- Market Cap
- $187.67 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.81%
- Days to Cover
- 1.29
About Entrada Therapeutics, Inc. Common Stock
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Related Stocks
Compare head-to-head: TRDA vs LLY·TRDA vs JNJ·TRDA vs ABBV·TRDA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.